Celgene and Juno partner in CART/TCR deal worth $1bn up front
Celgene Corp. and Juno Therapeutics Inc. entered into a major ten-year alliance that sees both partners benefiting from the other’s immunotherapeutics expertise, with an initial focus on T-cell receptor (TCR)- and chimeric antigen receptor T-cell (CART)-based treatments for cancer and autoimmune diseases.
- Gene Therapy, Cell Therapy
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.